Aldehyde-modified proteins as mediators of early inflammation in atherosclerotic disease

Derrick T. Antoniak, Michael J. Duryee, Ted R Mikuls, Geoffrey Milton Thiele, Daniel R Anderson

Research output: Contribution to journalReview article

19 Citations (Scopus)

Abstract

Inflammation is widely accepted to play a major role in atherosclerosis and other cardiovascular diseases. However, the exact mechanism(s) by which inflammation exerts its pathogenic effect remains poorly understood. A number of oxidatively modified proteins have been associated with cardiovascular disease. Recently, attention has been given to the oxidative compound of malondialdehyde and acetaldehyde, two reactive aldehydes known to covalently bind and adduct macromolecules. These products have been shown to form stable malondialdehyde-acetaldehyde (MAA) adducts that are reactive and induce immune responses. These adducts have been found in inflamed and diseased cardiovascular tissue of patients. Antibodies to these adducted proteins are measurable in the serum of diseased patients. The isotypes involved in the immune response to MAA (i.e., IgM, IgG, and IgA) are predictive of atherosclerotic disease progression and cardiovascular events such as an acute myocardial infarction or coronary artery bypass grafting. Therefore, it is the purpose of this article to review the past and current knowledge of aldehyde-modified proteins and their role in cardiovascular disease.

Original languageEnglish (US)
Pages (from-to)409-418
Number of pages10
JournalFree Radical Biology and Medicine
Volume89
DOIs
StatePublished - Dec 1 2015

Fingerprint

Inflammation Mediators
Aldehydes
Acetaldehyde
Cardiovascular Diseases
Malondialdehyde
Proteins
Inflammation
Macromolecules
Coronary Artery Bypass
Immunoglobulin A
Immunoglobulin M
Disease Progression
Atherosclerosis
Immunoglobulin G
Myocardial Infarction
Tissue
Antibodies
Serum

Keywords

  • Acetaldehyde
  • Antibodies
  • Atherosclerosis
  • Cardiovascular disease
  • Free radicals
  • Immune response
  • Malondialdehyde
  • Oxidative stress
  • Protein adduction

ASJC Scopus subject areas

  • Biochemistry
  • Physiology (medical)

Cite this

Aldehyde-modified proteins as mediators of early inflammation in atherosclerotic disease. / Antoniak, Derrick T.; Duryee, Michael J.; Mikuls, Ted R; Thiele, Geoffrey Milton; Anderson, Daniel R.

In: Free Radical Biology and Medicine, Vol. 89, 01.12.2015, p. 409-418.

Research output: Contribution to journalReview article

@article{ce304468a6c441da8e7415dcc9780b79,
title = "Aldehyde-modified proteins as mediators of early inflammation in atherosclerotic disease",
abstract = "Inflammation is widely accepted to play a major role in atherosclerosis and other cardiovascular diseases. However, the exact mechanism(s) by which inflammation exerts its pathogenic effect remains poorly understood. A number of oxidatively modified proteins have been associated with cardiovascular disease. Recently, attention has been given to the oxidative compound of malondialdehyde and acetaldehyde, two reactive aldehydes known to covalently bind and adduct macromolecules. These products have been shown to form stable malondialdehyde-acetaldehyde (MAA) adducts that are reactive and induce immune responses. These adducts have been found in inflamed and diseased cardiovascular tissue of patients. Antibodies to these adducted proteins are measurable in the serum of diseased patients. The isotypes involved in the immune response to MAA (i.e., IgM, IgG, and IgA) are predictive of atherosclerotic disease progression and cardiovascular events such as an acute myocardial infarction or coronary artery bypass grafting. Therefore, it is the purpose of this article to review the past and current knowledge of aldehyde-modified proteins and their role in cardiovascular disease.",
keywords = "Acetaldehyde, Antibodies, Atherosclerosis, Cardiovascular disease, Free radicals, Immune response, Malondialdehyde, Oxidative stress, Protein adduction",
author = "Antoniak, {Derrick T.} and Duryee, {Michael J.} and Mikuls, {Ted R} and Thiele, {Geoffrey Milton} and Anderson, {Daniel R}",
year = "2015",
month = "12",
day = "1",
doi = "10.1016/j.freeradbiomed.2015.09.003",
language = "English (US)",
volume = "89",
pages = "409--418",
journal = "Free Radical Biology and Medicine",
issn = "0891-5849",
publisher = "Elsevier Inc.",

}

TY - JOUR

T1 - Aldehyde-modified proteins as mediators of early inflammation in atherosclerotic disease

AU - Antoniak, Derrick T.

AU - Duryee, Michael J.

AU - Mikuls, Ted R

AU - Thiele, Geoffrey Milton

AU - Anderson, Daniel R

PY - 2015/12/1

Y1 - 2015/12/1

N2 - Inflammation is widely accepted to play a major role in atherosclerosis and other cardiovascular diseases. However, the exact mechanism(s) by which inflammation exerts its pathogenic effect remains poorly understood. A number of oxidatively modified proteins have been associated with cardiovascular disease. Recently, attention has been given to the oxidative compound of malondialdehyde and acetaldehyde, two reactive aldehydes known to covalently bind and adduct macromolecules. These products have been shown to form stable malondialdehyde-acetaldehyde (MAA) adducts that are reactive and induce immune responses. These adducts have been found in inflamed and diseased cardiovascular tissue of patients. Antibodies to these adducted proteins are measurable in the serum of diseased patients. The isotypes involved in the immune response to MAA (i.e., IgM, IgG, and IgA) are predictive of atherosclerotic disease progression and cardiovascular events such as an acute myocardial infarction or coronary artery bypass grafting. Therefore, it is the purpose of this article to review the past and current knowledge of aldehyde-modified proteins and their role in cardiovascular disease.

AB - Inflammation is widely accepted to play a major role in atherosclerosis and other cardiovascular diseases. However, the exact mechanism(s) by which inflammation exerts its pathogenic effect remains poorly understood. A number of oxidatively modified proteins have been associated with cardiovascular disease. Recently, attention has been given to the oxidative compound of malondialdehyde and acetaldehyde, two reactive aldehydes known to covalently bind and adduct macromolecules. These products have been shown to form stable malondialdehyde-acetaldehyde (MAA) adducts that are reactive and induce immune responses. These adducts have been found in inflamed and diseased cardiovascular tissue of patients. Antibodies to these adducted proteins are measurable in the serum of diseased patients. The isotypes involved in the immune response to MAA (i.e., IgM, IgG, and IgA) are predictive of atherosclerotic disease progression and cardiovascular events such as an acute myocardial infarction or coronary artery bypass grafting. Therefore, it is the purpose of this article to review the past and current knowledge of aldehyde-modified proteins and their role in cardiovascular disease.

KW - Acetaldehyde

KW - Antibodies

KW - Atherosclerosis

KW - Cardiovascular disease

KW - Free radicals

KW - Immune response

KW - Malondialdehyde

KW - Oxidative stress

KW - Protein adduction

UR - http://www.scopus.com/inward/record.url?scp=84943635058&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84943635058&partnerID=8YFLogxK

U2 - 10.1016/j.freeradbiomed.2015.09.003

DO - 10.1016/j.freeradbiomed.2015.09.003

M3 - Review article

C2 - 26432980

AN - SCOPUS:84943635058

VL - 89

SP - 409

EP - 418

JO - Free Radical Biology and Medicine

JF - Free Radical Biology and Medicine

SN - 0891-5849

ER -